Vaccines & Therapeutics Outlook Part I: Timelines and Success Factors · page 11 of 34
The slide highlights the unprecedented nature of the COVID-19 vaccine development effort as of August 2020.
Consulting deck · industry_trends · establish_context · dense density
Slide locked Sign in to view
Slide schematic 5/7
callout 0/1 chart 1/1 list 1/1 metric 0/1 paragraph 1/1 source-note 1/1 title 1/1
2 without position callout 1 · metric 1
calloutmetric · primary
Components 7
callout bar-vertical bullet primary paragraph source-note headline
Tools 4
Scarcity block · 55%
Word unprecedented positions the timeline as a rare window.
Action Titles slide · 85%Title states unprecedented response globally on scale and speed.
Chart Selection Guide slide · 70%The slide features a bar chart comparing the number of vaccine candidates in clinical and pre-clinical trials across diseases.
Concrete Language slide · 80%Specific dollar amounts: US $5.8B, Germany $1B, UK $0.5B.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.